Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Alimentary Pharmacology & Therapeutics|November 25, 2022
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis BJosef Wagner, Lilly Yuen, Margaret Littlejohn, et al.
Journal of Virology|November 11, 2011
Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative diseaseChristopher P Desmond, Silvana Gaudieri, Ian R James, et al.
Ebiomedicine|December 11, 2022
HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapyJennifer M Zerbato, Anchalee Avihingsanon, Kasha P Singh, et al.
The Lancet. Gastroenterology & Hepatology|April 15, 2019
A global scientific strategy to cure hepatitis BPeter A Revill, Francis V Chisari, Joan M Block, et al.
Hepatology (Baltimore, Md.)|August 12, 2020
Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease PhaseJosef Wagner, Lilly Yuen, Margaret Littlejohn, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
The Journal of General Virology|May 17, 2024
Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus, Lena Allweiss, Chari Cohen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Pageof 6